We are live on ! Find out more
71.40 USD
-1.62
2.22%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
71.75
+0.35
0.49%
1 day
-2.22%
5 days
-3.77%
1 month
-3.46%
3 months
-9.29%
6 months
-39.16%
Year to date
-43.3%
1 year
-51.46%
5 years
-64.05%
10 years
41.89%
 

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 14,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 9.1%
Neutral 85.5%
Negative 5.4%
Neutral
Zacks Investment Research
7 hours ago
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Negative
Seeking Alpha
16 hours ago
Zoetis: The Worst May Be Priced In
Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.
Zoetis: The Worst May Be Priced In
Negative
MarketBeat
1 day ago
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Positive
Seeking Alpha
1 day ago
Zoetis: An Undervalued Compounder Hiding In Plain Sight
Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.
Zoetis: An Undervalued Compounder Hiding In Plain Sight
Neutral
Seeking Alpha
4 days ago
Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Negative
Finbold
9 days ago
‘Big Short' Michael Burry just updated his portfolio for September
Michael Burry, a hedge fund manager and investor known for predicting the 2008 financial crash, has just updated his portfolio, with some notable new positions catching the market's attention.
‘Big Short' Michael Burry just updated his portfolio for September
Positive
Seeking Alpha
16 days ago
Top 25 High-Growth Dividend Stocks For September 2026
The September 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading below intrinsic value with strong long-term return potential. The list offers an average starting yield of 1.21%, appears 23% undervalued by dividend yield theory, and projects a 22.43% annualized long-term return. Stocks are grouped into Deep Value, Growth At A Price, and Balanced Opportunities, each bucket reflecting different valuation and growth profiles.
Top 25 High-Growth Dividend Stocks For September 2026
Neutral
Business Wire
16 days ago
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be ava.
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Positive
Seeking Alpha
18 days ago
Top 25 Dividend Stock Opportunities For September 2026
I present a screened list of 25 quality dividend growth stocks for September, emphasizing fundamental growth, economic moats, and yields above 2.5%. The top 25 stocks average a 3.11% yield and are undervalued by ~11% per Dividend Yield Theory, with a projected future CAGR of 14.43%. Key opportunities include high-yielders (e.g., Pepsi, American Tower); fast dividend growers (Autoliv, Yum China Brands); and deeply discounted names (Zoetis, Accenture).
Top 25 Dividend Stock Opportunities For September 2026
Positive
Seeking Alpha
1 month ago
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Price charts implemented using Lightweight Charts™